Abbott, Nevro tout spinal cord stimulation tech

Share

Nevro, AbbottAbbott (NYSE:ABT) and Nevro (NYSE:NVRO) touted their spinal cord stimulation technologies at the annual North American Neurological Society meeting in Las Vegas.

Two-year data from Abbott’s 42-patient Sunburst study revealed that a majority of patients chose its BurstDR therapy when given the choice during the long-term follow-up period and that stimulation from BurstDR provided pain relief through 24 months.

Get the full story on our sister site MassDevice.

From the Hospital Bed to the Finish Line

textadimage Heidi Dohse was diagnosed with a rare arrhythmia in 1982 and has been 100% pacemaker dependent for over 30 years. With the help of wearable devices, she has been able to pursue her dream to become a competitive cyclist.

You can hear her story and more when you register for DeviceTalks Boston, October 8-10.

REGISTER NOW

Use code FINISHLINE to save an additional 10%.

Speak Your Mind

*